Codexis (CDXS) Q4 2025 earnings review
Merck Deal Rescues Quarter and Secures Runway, But Core Operations Remain in Flux
Codexis achieved a sudden, reversing return to profitability in Q4, but it was entirely engineered by a one-time $37.8M Technology Transfer Agreement with Merck. This non-dilutive cash injection masked a severe 41% YoY collapse in legacy product revenue. Management is executing a hard pivot away from its historical small molecule biocatalysis business toward its ECO Synthesis RNAi manufacturing platform. The Merck capital, combined with a recent 24% headcount reduction, successfully extends the cash runway through 2027, buying the company critical time to scale its new GMP facilities and convert its 55 pipeline opportunities into recurring revenue.
🐂 Bull Case
The Merck agreement and Q4 restructuring extended the cash runway through 2027. Ending the year with $78.2M in cash removes near-term existential financing risks.
The company is now engaging with over 40 companies on 55 potential opportunities for its ECO Synthesis platform, advancing from feasibility tests to IND-enabling studies.
🐻 Bear Case
Product revenue fell 41% YoY to $5.8M in Q4. Management is actively de-emphasizing this segment, creating a dangerous revenue gap before the ECO platform fully scales.
The company is transitioning into a full-service CDMO. Building out the newly leased GMP facility for kilogram-scale production by late 2027 carries immense operational and regulatory risks.
⚖️ Verdict: ⚪
Neutral. The Merck deal was a masterful lifeline that definitively solves the near-term cash problem. However, the underlying transition remains highly risky, with legacy revenues plunging and the new platform still years away from mature commercial scale.
Key Themes
Merck Agreement Distorts Q4 Growth
Q4 Total Revenue grew an accelerating 81% YoY to $38.9M, but this was entirely driven by the $37.8M Merck Technology Transfer Agreement, which booked under R&D revenue. Without this deal, Q4 would have been a catastrophic revenue miss. This lumpiness highlights the transitional nature of the current business model.
Core Product Revenue Evaporating
A major concern is the accelerating decline in legacy product sales, which fell from $9.8M in 24Q4 to $5.8M in 25Q4. Management is explicitly redirecting focus away from the historical small molecule business due to pricing pressures. This creates a reliance on irregular licensing and tech transfer deals to bridge the gap until ECO Synthesis matures.
The CDMO Pivot Becomes Real
Codexis is officially building its own manufacturing footprint. The company signed a lease for a GMP facility capable of kilogram-scale siRNA manufacturing, expecting retrofit construction to begin in H2 2026 with full production capability by end-of-2027. This transitions Codexis from an enzyme supplier to a full-service CDMO.
Product Margins Structurally Improving
Despite falling volumes, Product Gross Margin showed a stable, positive trend, reaching 65% in Q4 (up from 63% a year ago) and 64% for the full year. Management attributes this to a deliberate mix shift toward higher-margin products and the intentional retirement of less profitable legacy enzymes.
Technological Edge: Stereoisomer Control
On the innovation front, Codexis unveiled data at TIDES US demonstrating that ECO Synthesis can deliver defined stereochemistry in oligonucleotide products. Chemical approaches often struggle with this, producing mixtures. Offering precise chirality control gives Codexis a unique selling point to boost the therapeutic potency of customer drug assets.
Restructuring Reduces Operating Bloat
The company recorded a $3.4M restructuring charge in Q4 related to a previously announced reduction in force. This discipline is evident in operating expenses: Q4 SG&A fell 14% YoY to $11.2M, and Q4 R&D fell to $11.7M, creating a leaner cost structure for the transition years ahead.
Macro Tailwinds: RNAi Market Expansion
The external environment remains a strong tailwind. The broader siRNA therapeutic field is evolving rapidly, and customers are increasingly looking for scalable, onshore manufacturing solutions to avoid supply chain risks associated with overseas (specifically Chinese) production. Codexis's enzymatic approach requires 70% less capital expenditure to stand up than traditional chemical methods, directly addressing this macro need.
Other KPIs
A reversing, positive trend. Cash balances had been bleeding down (from $98M at end-of-2023 to $58.7M in 25Q3), but the Merck payment replenished the war chest. This balance completely de-risks the near-term, pushing the cash runway through the end of 2027.
An improvement from the -$58.5M loss in 2024. While the company posted a Q4 net income of $9.6M, the full-year operating loss reflects the true underlying burn rate of the business prior to the Merck cash infusion.
Guidance
Decelerating. The midpoint of $74M implies only ~5% YoY growth compared to FY25's $70.4M. Given that FY25 included a massive $37.8M one-time Merck deal, achieving $74M in FY26 implies that management expects significant new recurring contracts or alternative milestone payments to replace that void.
Stable. Upgraded from prior guidance which only projected runway through the end of 2026. This extension is a direct result of the Merck agreement and Q4 headcount reductions, giving the company the necessary buffer to complete its GMP facility retrofit.
Key Questions
Bridging the FY26 Revenue Guide
With the $37.8M Merck deal not repeating, the $72-$76M guidance for FY26 implies a massive replacement of revenue. What is the specific breakdown of this guide between legacy product sales, ligase contracts, and new ECO Synthesis development milestones?
GMP Facility CapEx Timing
You plan to begin retrofit construction on the GMP facility in H2 2026. What is the anticipated total capital expenditure for this build-out, and how does it impact cash burn modeling between now and the 2027 operational target?
CDMO Partnership Economics
Regarding the agreement with Axolabs to evaluate integrating ECO Synthesis into their site: what does the economic model look like if they adopt it? Is it a royalty, a technology licensing fee, or a raw material supply arrangement?